DONG-A ST CO.,LTD Logo

DONG-A ST CO.,LTD

Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.

170900 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울 동대문구 용두동 138 ~255 천호대로 64, 서울
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dong-A ST Co., Ltd. is a specialized pharmaceutical and medical device company that spun off from Dong-A Socio Group in 2013. The company focuses on the development, manufacturing, and global distribution of ethical drugs (ETC), medical devices, and diagnostics. Its pharmaceutical portfolio includes domestically developed new drugs such as Stillen and Zydena, biopharmaceuticals, and chemical drugs. Dong-A ST is also a major global manufacturer of the tuberculosis API, Cycloserine. The medical device and diagnostics division provides comprehensive healthcare solutions in areas including ENT (Ear, Nose, Throat) equipment, in-vitro diagnostics, and infection control systems. With a strong emphasis on research and development, the company actively pursues international expansion through global partnerships and exports.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for DONG-A ST CO.,LTD and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-09 00:00
Prospectus
투자설명서
Korean 2.8 MB
2025-09-09 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 47.8 KB
2025-09-08 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 14.6 KB
2025-09-03 00:00
Registration Form
[기재정정]증권신고서(채무증권)
Korean 3.1 MB
2025-09-03 00:00
Prospectus
[발행조건확정]증권신고서(채무증권)
Korean 275.8 KB
2025-08-28 00:00
Registration Form
증권신고서(채무증권)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.3 MB
2025-08-13 00:00
Earnings Release
[기재정정]영업(잠정)실적(공정공시)
Korean 18.0 KB

Automate Your Workflow. Get a real-time feed of all DONG-A ST CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for DONG-A ST CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.